MMED (NASDAQ:MMED) Earns Overweight Rating from Analysts at Wells Fargo & Company

Analysts at Wells Fargo & Company started coverage on shares of MMED (NASDAQ:MMED) in a research note issued on Tuesday. The firm set an “overweight” rating and a $26.00 price target on the stock. Wells Fargo & Company‘s price target would suggest a potential upside of 81.18% from the company’s previous close.

MMED has been the subject of several other research reports. Evercore initiated coverage on shares of MMED in a research report on Tuesday. They set an “outperform” rating and a $20.00 price objective for the company. Mizuho began coverage on shares of MMED in a research note on Tuesday. They set an “outperform” rating and a $21.00 price target on the stock. Morgan Stanley initiated coverage on shares of MMED in a research note on Tuesday. They issued an “overweight” rating and a $19.00 price objective for the company. BTIG Research initiated coverage on MMED in a report on Tuesday. They issued a “buy” rating and a $25.00 target price for the company. Finally, Citigroup started coverage on MMED in a research note on Tuesday. They set a “buy” rating and a $23.00 price target on the stock. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $22.33.

MMED Stock Down 0.8%

Shares of MMED opened at $14.35 on Tuesday. MMED has a 52-week low of $14.10 and a 52-week high of $20.48.

MMED Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.